TERT and neoplasm: While this provided excellent specificity and high sensitivity for classical PTC, it does not cover the mutational spectrum of FVPTC, follicular thyroid carcinoma (FTC), and some low-risk neoplasms, which are frequently associated with RAS family mutations or, in the case of more aggressive tumors, TERT promoter mutations.